About this trial
Patients with acute ischemic stroke who have undergone endovascular thrombectomy will be eligible to be included, and thrombus will be collected after obtaining informed consent. Enrolled patients will receive a comprehensive diagnostic evaluation and the best medical treatment according to recent stroke management guidelines. The mechanism of the stroke will be classified into atherosclerotic, cardiac embolism, others and unknown causes based on diagnostic workup. Patients will be monitored in an outpatient clinic for vascular events including stroke recurrence, death, and bleeding events, which will continue for up to two years after the initial stroke event. Thrombus information related to RNA expression patterns and histological characteristics will be analyzed to classify the stroke mechanism and predict future vascular events after the initial stroke.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
patients with acute ischemic stroke who had undergone endovascular thrombectomy
Disqualifiers
None
Trial population
patients with acute ischemic stroke who had undergone endovascular thrombectomy and agreed to participate to the study
Trial design
Cohort
Prospective
Treatments tested in this trial
thrombus analysis
Diagnostic testDetailed expression pattern of RNA and histological characteristics will be investigated.
Treatment groups
Trial outcomes
Primary outcomes
Vascular events
major vascular events after endovascular thrombectomy, including stroke, myocardial infarction, and vascular death
Secondary outcomes
Thromboembolic events
Any thromboembolic events after endovascular thrombectomy including ischemic stroke, transient ischemic attack, myocardial infarction or unstable angina, peripheral artery disease requiring hospitalization, venous thromboembolism, pulmonary embolism and vascular death
Other outcomes
overall mortality
any death event after endovascular thrombectomy
Sponsors and contacts
Click on the lead sponsor to view all of their trials.